Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
These sessions are reserved for first presentation of the primary endpoint(s) of novel clinical trials, recently completed and unpublished. Each will immediately be followed by a review from a renowned expert on the outcome presented.
New this year –The audience will be invited to interact during the presentations by answering questions when prompted and by using "Ask" to send their questions directly to the Mobile App. Incoming questions Moderator.
Use your Mobile App to answer and send questions during the session.
Hot Line Session 1
Sunday 26 August - 14:30 - 15:45 Munich - Main Auditorium
MARINER - Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk
CAMELLIA-TIMI 61 - Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61
ARRIVE - Aspirin to Reduce Risk of Initial Vascular Events
Hot Line Session 2
Sunday 26 August - 16:45 - 17:45 Munich – Main Auditorium
ASCEND - A randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes
ASCEND - A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 people with diabetes
ART - Randomised comparison of bilateral versus single internal thoracic coronary artery bypass graft surgery: effects on mortality at ten years follow-up in the Arterial Revascularisation Trial
Hot Line Session 3
Monday 27 August - 11:00 - 12:30 Munich – Main Auditorium
ATTR-ACT - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy
COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
MITRA.fr study - A randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation and reduced left ventricular ejection fraction
GLOBAL LEADERS TRIAL - A randomized comparison of 24 month ticagrelor and 1 month aspirin versus 12 month dual antiplatelet therapy followed by aspirin monotherapy
Hot Line Session 4
Tuesday 28 August - 11:00 - 12:30 Munich – Main Auditorium
PURE - Association of dietary quality and risk of cardiovascular disease and mortality in more than 218,000 people from over 50 countries
FREED - Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy
BASKET-SMALL 2 - Drug-Coated Balloons vs. Drug- Eluting Stents in Small Vessel Interventions
VERDICT - Early versus deferred invasive examination and treatment of patients with Non-ST-segment elevation acute coronary syndrome
Hot Line Session 5
Tuesday 28 August - 14:30 - 15:45 Munich – Main Auditorium
High-STEACS - High-Sensitivity Troponin in the Evaluation of patients with Acute Coronary Syndrome
POET - Partial oral treatment of left-sided infectious endocarditis
AIMS - Aortic Irbesartan Marfan Study
Also not to be missed – Meet the Trialist sessions – View details
These sessions provide an unique opportunity for a focus on the trial with direct interaction with the audience. An opportunity for a deep-dive in the trial with the presenter and an expert in the topic animating discussions with questions to both the presenter and the audience.
Our mission: To reduce the burden of cardiovascular disease.
© 2019 European Society of Cardiology. All rights reserved.